Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Peritoneal mesothelioma, drawn from the whole corpus: 3 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
No randomised trial has compared surgery plus HIPEC with systemic therapy.
Selection for surgery relies on centre experience rather than validated criteria.
Peritoneal patients were excluded from the pleural immunotherapy trials, so their benefit is inferred.
Nothing recorded yet.
Also on OnCo: Atlas of advanced disease · How cancer spreads: the metastasis stages.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 5 changes by month →When this page itself was last checked or edited.
Early phase 2 and retrospective data for nivolumab plus ipilimumab and for atezolizumab plus bevacizumab.
Yan and colleagues report median survival of 53 months after cytoreduction and HIPEC.
Peritonectomy procedures and heated intraperitoneal chemotherapy applied to peritoneal surface malignancy.
Among the earliest descriptions of a primary tumour of the peritoneum.